GlassScriptPhysician profile
Steven R Ross
NPI 1689647943
$3,454.71
in general payments reported to CMS, 2019-2025
39 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $279 · 2021: $652 · 2022: $379 · 2023: $522 · 2024: $574 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $483.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $415.05 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $237.31 | 2019-2025 | Verquvo, Capvaxive |
| Sumitomo Pharma America, INC. | $210.33 | 2023-2025 | Gemtesa |
| Abbvie INC. | $209.85 | 2021-2023 | Vraylar, Ubrelvy, Synthroid |
| Esperion Therapeutics, INC. | $186.60 | 2023-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.87 | 2020-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $161.04 | 2019-2023 | |
| Abbott Laboratories | $148.82 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $143.81 | 2020-2021 | |
| Pfizer INC. | $122.74 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $98.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $83.49 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $83.36 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Eisai INC. | $65.58 | 2020-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.19 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $52.02 | 2025 | Cologuard Collection Kit |
| Aytu Biopharma, INC. | $49.74 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.64 | 2023-2024 | Caplyta |
| Radius Health, INC. | $38.38 | 2024-2025 | |
| Cvrx, INC. | $37.88 | 2024 | Barostim Neo System |
| Boston Scientific Corporation | $37.16 | 2022-2024 | Watchman Flx |
| Dexcom, INC. | $36.60 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $31.33 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $31.21 | 2024 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $19.59 | 2023 | Rexulti |
| Corcept Therapeutics | $19.32 | 2024 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $18.81 | 2021 | |
| Bausch Health US, LLC | $18.24 | 2024 | Aplenzin |
| Acadia Pharmaceuticals INC | $16.41 | 2025 | Nuplazid |
| Sanofi Pasteur INC. | $16.41 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.94 | 2023 | |
| Axsome Therapeutics, INC. | $15.66 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $15.40 | 2024 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $14.79 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $14.66 | 2023 | Rexulti |
| Currax Pharmaceuticals LLC | $14.18 | 2021 | |
| Shield Therapeutics INC | $14.06 | 2024 | |
| Allergan, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.